Knight Therapeutics (OTCMKTS:KHTRF) has been assigned a $10.30 target price by research analysts at Raymond James in a note issued to investors on Wednesday, TipRanks reports. The firm presently has a “buy” rating on the stock. Raymond James’ price target suggests a potential upside of 84.13% from the company’s previous close.
KHTRF stock traded up $0.02 during midday trading on Wednesday, reaching $5.59. The company had a trading volume of 200 shares, compared to its average volume of 3,341. The stock has a 50 day moving average price of $5.68 and a 200-day moving average price of $5.64. Knight Therapeutics has a 1-year low of $5.30 and a 1-year high of $6.53.
About Knight Therapeutics
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; and NERLYNX for the treatment of HER2-positive breast cancer.
See Also: Market Capitalization in the Stock Market
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.